Suppr超能文献

口腔癌中危因素的辅助治疗:我们能否达成共识?

Adjuvant therapy for intermediate risk factors in oral cancer: Can we reach a consensus?

机构信息

Division of Head and Neck Oncology, Apollo Cancer Hospitals, Mumbai 400614, India.

Department of Radiotherapy, Tata Memorial Hospital, Mumbai 400012, India.

出版信息

Oral Oncol. 2024 Oct;157:106972. doi: 10.1016/j.oraloncology.2024.106972. Epub 2024 Jul 30.

Abstract

Oral carcinoma is a common disease that poses challenges in treatment management, especially for advanced cases. Adjuvant therapies, such as radiation and chemoradiation therapy, are typically used for advanced oral cancer patients. However, there is uncertainty regarding the use of adjuvant therapy for early-stage patients with certain soft histological parameters. The UICC manual of clinical oncology suggests that adjuvant therapy for such parameters is desirable but not essential. These parameters include perineural invasion, lymphovascular invasion, single nodal positivity, and patterns of invasion, which complicate the decision-making process for including adjuvant therapy. This review aims to provide evidence-based literature for effectively managing this patient group and developing treatment protocols based on current evidence.

摘要

口腔癌是一种常见疾病,在治疗管理方面存在挑战,尤其是对于晚期病例。辅助治疗,如放疗和放化疗,通常用于晚期口腔癌患者。然而,对于某些软组织学参数处于早期阶段的患者,使用辅助治疗存在不确定性。UICC 临床肿瘤学手册建议,对于这些参数,辅助治疗是可取的,但不是必需的。这些参数包括神经周围侵犯、血管侵犯、单个淋巴结阳性和浸润模式,这使得是否包括辅助治疗的决策过程变得复杂。本综述旨在提供循证文献,以有效管理这组患者,并根据现有证据制定治疗方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验